Introduction: Trastuzumab is generally considered a highly safe drug, but there have been cases of infusion reaction and cardiotoxicity. This report will present a rare case of hepatotoxicity induced by trastuzumab used for adjuvant therapy of human epidermal growth factor receptor type 2-positive breast cancer.
Introduction
Trastuzumab is generally considered a highly safe drug, but there have been cases of infusion reaction and cardiotoxicity [1] [2] [3] [4] . We report here a rare case of hepatotoxicity induced by trastuzumab used for adjuvant therapy of human epidermal growth factor receptor type 2 (HER2)-positive breast cancer and we also include a brief literature review.
Case presentation
The patient was a 60-year-old postmenopausal Japanese woman with non-contributory past medical history, alcohol use at a social drinking level, and no history of cigarette smoking. An abnormality was found in her left breast during a physical examination at another hospital, and she was referred and presented to our hospital for a detailed examination in October 2011. The results of the examination revealed left breast cancer (T2N1M0, stage IIB) that was positive for estrogen receptor and progesterone receptor and was HER2 3+. The treatment plan was neoadjuvant chemotherapy. In November, she began receiving epirubicin and cyclophosphamide therapy (epirubicin 75mg/m 2 , cyclophosphamide 600mg/m 2 , day 1 every 3 weeks) but developed hepatotoxicity: aspartate aminotransferase (AST) 43U/L (Grade 1), alanine aminotransferase (ALT) 104U/L (Grade 1), alkaline phosphatase (ALP) 634U/L (Grade 1), and glutamyl transpeptidase (γ-GTP) 383U/L (Grade 3). Thus, the therapy was discontinued after two cycles, and a weekly paclitaxel (PTX) therapy (80mg/m 2 on days 1, 8, and 15; every 4 weeks) was begun. After the absence of adverse events was confirmed, she also began receiving trastuzumab at a loading dose (4mg/kg) beginning with the second cycle. However, hepatotoxicity (AST 267U/L, Grade 3; ALT 246U/L, Grade 3; ALP 553U/L, Grade 1; and γ-GTP 240U/L, Grade 3) developed again, and trastuzumab was discontinued. There was no elevated bilirubin or abnormality in coagulation tests. After liver functions improved, she received PTX monotherapy for a total of four cycles. In August 2012, she underwent partial mastectomy and axillary dissection, and the pathological diagnosis was papillotubular carcinoma with a depth of invasion of 1.2cm, n-, ly0, v0, negative margin, and histological response to chemotherapy of grade 1b. After completing adjuvant radiation therapy (breast, 50Gy), she was readministered trastuzumab (4mg/kg) beginning in May 2013, but hepatotoxicity (AST 47U/L, Grade 1; ALT 102U/L, Grade 1; ALP 377U/L, Grade 1; and γ-GTP 91U/L, Grade 2) recurred. Thus, it was discontinued again (Figure 1 ). She was negative for hepatitis C virus antibody and hepatitis B virus DNA, and there was no hepatitis B or C virus infection. A druginduced lymphocyte stimulation test (DLST) revealed a positive reaction to trastuzumab (stimulation index: 227%). Thereafter she has used only oral letrozole (2.5mg/day) and no recurrent cancer has been observed as of May 2014.
Discussion
Overexpression of HER2 protein occurs in 20 to 30% of breast cancers and is considered a predictor of poor prognosis [5, 6] . The prognosis of patients with such cancer has improved greatly with the emergence of the molecularly targeted drug trastuzumab [7, 8] . Therefore, it is presently used for advanced and metastatic breast cancer and is also used frequently for adjuvant therapy. It is a major drug for treatment of HER2-positive breast cancer.
The most significant adverse events of trastuzumab are serious infusion reactions and cardiotoxicity [1] [2] [3] [4] . Other serious adverse events are rare in general clinical practice. In particular, trastuzumab-induced hepatotoxicity is rare and there are only three past reports in the English literature. These reports are described below.
In one report, Muñoz et al. presented a case of HER2-positive breast cancer that underwent surgery and adjuvant trastuzumab therapy (8mg/kg). The patient developed hepatotoxicity (AST, Grade 3; ALT, Grade 4), but liver function tests showed normal values 1 month after trastuzumab was discontinued. Therefore, trastuzumab was reintroduced at 2mg/kg every week and she completed 1 year of treatment without recurrence of hepatotoxicity. This patient had received fluorouracil, doxorubicin, and cyclophosphamide therapy up to 1 month before trastuzumab was begun and had hepatotoxicity (AST, Grade 3; ALT, Grade 4). These authors discussed that trastuzumab probably caused hepatotoxicity in a dose-dependent manner, but chemotherapyinduced hepatotoxicity also probably played a role in trastuzumab-induced hepatotoxicity [9] .
In another report, Srinivasan et al. presented a case of HER2-positive breast cancer that underwent neoadjuvant therapy (weekly PTX and trastuzumab). Consequently, the patient developed hepatotoxicity (AST and ALT, Grade 3; ALP, Grade 2). When trastuzumab was reintroduced as monotherapy after surgery, she once again developed hepatotoxicity (AST and ALT, Grade 3; ALP, Grade 2) [10] .
In still another report, Vucicevic et al. reported on a case of HER2-positive breast cancer in which adjuvant trastuzumab monotherapy was used. The patient developed hepatotoxicity 6 months after the first administration. In this patient, the transaminase level continued to elevate for 2 months after trastuzumab was discontinued (AST and ALT, Grade 3; ALP, Grade 2), but the results of her liver function tests were normal on the fourth month. These authors thought that the long half-life of trastuzumab was a cause of prolonged hepatotoxicity [11] .
Our patient did not have a family history of liver disease, was not taking any drug regularly, and had no hepatitis B or C virus infection. She was diagnosed with trastuzumab-induced hepatotoxicity. This diagnosis was based on the finding that hepatotoxicity developed not only for a combination of trastuzumab and PTX therapy but also for trastuzumab monotherapy and that the DLST revealed a positive reaction to trastuzumab.
Our patient is the fourth reported case of trastuzumabinduced hepatotoxicity based on our literature search and the first case in which trastuzumab was identified as the causative drug using DLST. Two of the previous reported cases had developed hepatotoxicity after the first administration of trastuzumab. However, one case had developed hepatotoxicity a while after beginning trastuzumab therapy and, therefore, caution is required. When trastuzumabinduced hepatotoxicity is detected early, liver dysfunction can be reversed and more serious complications can be prevented. Thus, periodic liver function tests are thought to be necessary during trastuzumab therapy.
Conclusions
Although trastuzumab is highly safe, one must be mindful of its risk for hepatotoxicity and periodically perform liver function tests during trastuzumab therapy.
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